JNK (c-Jun N-terminal kinase), a kinase subfamily belonging to the MAPK, is activated in response to various stress stimuli and possesses a wide variety of regulatory functions.Three isoforms of the serine/threonine protein kinase JNK family (JNK1, JNK2, and JNK3) exist. JNKs play a role in the development and progression of many pathologies, including cancer, inflammatory diseases, cardiovascular and metabolic disorders, and neurodegenerative diseases.
JNKs are triggered by a phosphorylation cascade that typically involves two different upstream kinases, the so-called MAP kinase kinase kinases (MAP3K, MKKK) and the MAP kinase kinases (MAP2K; MKK). This process is similar to that used to activate the other MAP kinases. JNKs are triggered by MKK4 and MKK7 at the MAP2K level; the former is a shared activator of the JNK and p38 MAP kinase signaling pathways. The JNK cascade is a component of a complicated signaling network since it crosses numerous other routes at different places.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V51546 | (-)-Zuonin A (D-Epigalbacin) | 84709-25-1 | natual lignin-based JNK inhibitor |
|
V51559 | 8-Hydroxy-efavirenz | 205754-33-2 | major metabolite of Efavirenz |
|
V10399 | AEG-3482 | 63735-71-7 | AEG-3482 is a novel and potent antiapoptotic compound. |
|
V0475 | Anisomycin (NSC-76712, AI 3-50846, Flagecidin, Wuningmeisu C) | 22862-76-6 | Anisomycin (Wuningmeisu C, NSC76712, AI3-50846, Flagecidin),a naturally occuringbacterial antibiotic isolated from Streptomyces griseolus, is a novel, potent and specific activator (agonist)of JNK (c-Jun N-terminal Kinase) with potential antineoplastic activity. |
|
V3732 | AS 602801 (Bentamapimod) | 848344-36-5 | AS602801 (also known as Bentamapimod and PGL5001) is a novel, potent and ATP-competitive JNK (c-Jun N-terminal Kinase) inhibitor with IC50 values of 80 nM, 90 nM, and 230 nM for JNK1, JNK2, and JNK3, respectively. |
|
V3735 | AS601245 | 345987-15-7 | AS601245 is an inhibitor of the JNK signaling pathway, it showed high JNK1/2/3 inhibition with IC50 of 150, 220, and 70 nM respectively. |
|
V2665 | BI-78D3 | 883065-90-5 | BI-78D3 (also known as JNK Inhibitor X) is a novel, potent and competitive JNK inhibitor with IC50 of 280nM. |
|
V2078 | CC-401 | 395104-30-0 | CC-401 (CC401) is a potent, specific, 2nd generation and ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. |
|
V2978 | CC-401 HCl | 1438391-30-0 | CC-401 HCl (CC401 hydrochloride) is an anthrapyrazolone-based inhibitor of c-Jun N terminal kinase (JNK) with potential anticancer activity. |
|
V2263 | CC-90001 | 1403859-14-2 | CC-90001 (CC90001; CC 90001) is a novel, potent and selective inhibitor of c-Jun N-terminal kinase (JNK) with potential anti-fibrotic activity. |
|
V19209 | DB07268 | 929007-72-7 | DB07268 is a potent and specific JNK1 inhibitor (antagonist) with IC50 of 9 nM. |
|
V51558 | Dehydrocrenatine | 26585-13-7 | β-carboline alkaloid |
|
V80005 | DN-1289 | DN-1289 is an orally bioactive, selective inhibitor targeting dileucine zipper kinase (DLK; IC50=17 nM) and leucine zipper-bearing kinase (LZK; IC50=40 nM). | |
|
V0474 | DTP3 | 1809784-29-9 | DTP3 (DTP-3) is a novel, potent and selective inhibitor of GADD45β/MKK7 ((growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) with potential anticancer activity. |
|
V22646 | IQ-1S | 23146-22-7 | IQ-1S is a potent and selective c-Jun N-Terminal Kinase Inhibitor. |
|
V51553 | JIP-1 (153-163) | 438567-88-5 | peptide-based JNK inhibitor |
|
V80447 | JIP-1(153-163) TFA (T1-JIP TFA) | JIP-1(153-163) TFA (TI-JIP TFA) is a bioactive peptide inhibitor of c-JNK. | |
|
V28892 | JNK Inhibitor VIII (TCS JNK 6o) | 894804-07-0 | JNK Inhibitor VIII (TCS JNK 6o) isa selective and ATP-competitive inhibitor of c-Jun N-terminal kinases (JNK-1, -2, and -3) with Kis of 2 nM, 4 nM, 52 nM, respectively, and has IC50 of 45 nM and 160 nM for JNK-1 and -2, respectively. |
|
V80254 | JNK-1-IN-2 | JNK-1-IN-2 (Compound c6) is a JNK-1 inhibitor (IC50= 33.5 nM). | |
|
V80459 | JNK-IN-12 | JNK-IN-12 (compound P2) is a mitochondria-targeted JNK inhibitor (IC50=66.3 nM), consisting of a mitochondria-specific cell-penetrable peptide and JNK-specific inhibitor SP600125. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
